Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burcu Aslan

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry|November 23, 2023
Evaluation of oral manifestations and head and neck lymphadenopathy in newly diagnosed acute leukemia patientsUmut Pamukcu, Mehmet Sinan Dal, Samet Yaman, et al.
Clinical Transplantation|July 20, 2024
Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center ExperienceSamet Yaman, Semih Başci, Ersin Bozan, et al.
Journal of Clinical Medicine|September 14, 2024
Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant SettingSinem Namdaroğlu, Semih Başcı, Burcu Aslan Candır, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|May 29, 2024
Is an earlier strategy for harvesting peripheral blood stem cells in healthy allogeneic donors feasible?Samet Yaman, Ersin Bozan, Sema Seçilmiş, et al.
Journal of Clinical Medicine|September 13, 2025
Cholesterol Levels Are Not Associated with Peripheral Blood Stem Cell Mobilization in Healthy DonorsSema Seçilmiş, Burcu Aslan Candır, Ersin Bozan, et al.
Oncotarget|November 3, 2023
Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinaseRecep Bayraktar, Martin Pichler, Pinar Kanlikilicer, et al.
Pharmaceuticals (Basel, Switzerland)|May 4, 2026
Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide EraSema Seçilmiş, Burcu Aslan Candır, Uğur Hatipoğlu, et al.
Blood Cancer Journal|May 20, 2022
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemiaBurcu Aslan, Gorkem Kismali, Lakesla R Iles, et al.
Research Square|April 16, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionVarsha Gandhi, Shady Tantawy, Burcu Aslan, et al.
Oncotarget|December 31, 2016
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinaseRecep Bayraktar, Martin Pichler, Pinar Kanlikilicer, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry|November 23, 2023
Evaluation of oral manifestations and head and neck lymphadenopathy in newly diagnosed acute leukemia patientsUmut Pamukcu, Mehmet Sinan Dal, Samet Yaman, et al.
Clinical Transplantation|July 20, 2024
Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center ExperienceSamet Yaman, Semih Başci, Ersin Bozan, et al.
Journal of Clinical Medicine|September 14, 2024
Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant SettingSinem Namdaroğlu, Semih Başcı, Burcu Aslan Candır, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|May 29, 2024
Is an earlier strategy for harvesting peripheral blood stem cells in healthy allogeneic donors feasible?Samet Yaman, Ersin Bozan, Sema Seçilmiş, et al.
Journal of Clinical Medicine|September 13, 2025
Cholesterol Levels Are Not Associated with Peripheral Blood Stem Cell Mobilization in Healthy DonorsSema Seçilmiş, Burcu Aslan Candır, Ersin Bozan, et al.
Oncotarget|November 3, 2023
Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinaseRecep Bayraktar, Martin Pichler, Pinar Kanlikilicer, et al.
Pharmaceuticals (Basel, Switzerland)|May 4, 2026
Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide EraSema Seçilmiş, Burcu Aslan Candır, Uğur Hatipoğlu, et al.
Blood Cancer Journal|May 20, 2022
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemiaBurcu Aslan, Gorkem Kismali, Lakesla R Iles, et al.
Research Square|April 16, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progressionVarsha Gandhi, Shady Tantawy, Burcu Aslan, et al.
Oncotarget|December 31, 2016
MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinaseRecep Bayraktar, Martin Pichler, Pinar Kanlikilicer, et al.
Pageof 4